Log in to search using one of your social media accounts:

 

Circulating Anti ‐Müllerian Hormone and Breast Cancer Risk: A Study in Ten Prospective Cohorts

Abstract A strong positive association has been observed between circulating anti‐Müllerian hormone (AMH), a biomarker of ovarian reserve, and breast cancer risk in three prospective studies. Confirming this association is important because of the paucity of biomarkers of breast cancer risk in premenopausal women. We conducted a consortium study including ten prospective cohorts that had collected blood from premenopausal women. A nested case‐control design was implemented within each cohort. A total of 2,835 invasive (80%) and in situ (20%) breast cancer cases were individually matched to controls (n = 3,122) on age at blood donation. AMH was measured using a high sensitivity enzyme‐linked immunoabsorbent assay. Conditional logistic regression was applied to the aggregated dataset. There was a statistically significant trend of increasing breast cancer risk with increasing AMH concentration (ptrend across quartiles 
Source: International Journal of Cancer - Category: Cancer & Oncology Authors: Tags: Research Article Source Type: research

Related Links:

ConclusionFor ER-positive premenopausal patients, the sequential use of GnRHa and chemotherapy showed ovarian preservation and survival outcomes that were no worse than simultaneous use. The application of GnRHa can probably be delayed until menstruation resumption after chemotherapy.
Source: Breast Cancer Research and Treatment - Category: Cancer & Oncology Source Type: research
Estrogen is a miracle drug for many women who experience the drenching sweats, sexual dysfunction and frustrating brain betrayals associated with entering menopause. It comes in expensive patches, less expensive pills or injections, as well as vaginal creams or rings. It has gone in and out of favor with the medical community for decades. Estrogen is the main ingredient in most birth control pills and has been studied extensively in that context as well as in the setting of women whose ovaries have ceased to produce it as they age. It can increase the risk of migraines, blood clots in the legs or lungs; it can cause benign...
Source: Kevin, M.D. - Medical Weblog - Category: General Medicine Authors: Tags: Conditions OB/GYN Source Type: blogs
Authors: Morarji K, McArdle O, Hui K, Gingras-Hill G, Ahmed S, Greenblatt EM, Warner E, Sridhar S, Ali AMF, Azad A, Hodgson DC Abstract Background: As cure rates for breast cancer improve, there is increasing evidence that late effects of treatment-and impaired fertility in particular-are emerging as important concerns among young breast cancer survivors. Older reports have evaluated the occurrence of amenorrhea after treatment, but few data have been reported about the incidence of biochemical evidence for impaired ovarian function in patients who do not become overtly menopausal. Methods: We conducted a cross...
Source: Current Oncology - Category: Cancer & Oncology Tags: Curr Oncol Source Type: research
Author Affiliations open 1Epidemiology Branch, National Institute of Environmental Health Sciences (NIEHS), National Institutes of Health (NIH), Department of Health and Human Services (DHHS), Research Triangle Park, North Carolina, USA 2Social &Scientific Systems, Inc., Durham, North Carolina, USA 3Westat, Durham, North Carolina, USA 4Department of Global Public Health and Primary Care, University of Bergen, Bergen, Norway 5Biostatistics and Computational Biology Branch, NIEHS, NIH, DHHS, Research Triangle Park, North Carolina, USA PDF Version (548 KB) Abstract About This Article Supplemental Material Bac...
Source: EHP Research - Category: Environmental Health Authors: Tags: Research Source Type: research
AbstractA 1-month formulation of the gonadotrophin-releasing hormone agonist (GnRHa) triptorelin (Decapeptyl®) has been approved in the EU as an adjuvant treatment in combination with tamoxifen or an aromatase inhibitor (AI), of endocrine-responsive, early-stage breast cancer in women at high risk of recurrence who are confirmed as premenopausal after completion of chemotherapy. This indication reflects the results of the 5-year SOFT and TEXT studies, especially SOFT, in which ovarian function suppression (OFS; mainly achieved with triptorelin) added to tamoxifen provided a significant benefit in the overall study popu...
Source: Drugs - Category: Drugs & Pharmacology Source Type: research
CONCLUSIONS: In both postmastectomy trials, patients with Luminal A tumors turned out to have a significant lower incidence of loco-regional recurrence when randomized to adjuvant radiotherapy, leaving no indication to omit postmastectomy adjuvant radiation in pre-menopausal high-risk patients with Luminal A tumors. It was not possible to evaluate the effect of radiotherapy among the other subtypes because of limited sample sizes. PMID: 29172851 [PubMed - as supplied by publisher]
Source: Acta Oncologica - Category: Cancer & Oncology Authors: Tags: Acta Oncol Source Type: research
I was a cancer expert long before I was a patient: in control, passionate about my work and invulnerable. Yet all of this would change with one phone call. It was a morning like many before. While discussing a complicated case with a colleague, my cell phone began to vibrate. Seeing the familiar number from the university’s radiology department, I knew it would be a “finding of concern.” With a pang of sadness, I pondered which of my patients I would soon be calling with bad news. The voice on the other end of the line sounded cheerful and upbeat. She told me that they had found five little “irregul...
Source: TIME.com: Top Science and Health Stories - Category: Consumer Health News Authors: Tags: Uncategorized Breast Cancer breast cancer diagnosis breast cancer treatment i have breast cancer oncologist oncology TIME Health Breast Cancer what is breast cancer Source Type: news
It’s not going to kill you to take hormone replacement therapy. That’s the take home message from the latest analysis of the Women’s Health Initiative, the largest and longest randomized trial of hormone replacement therapy (HRT) in menopausal women. After almost 18 years of follow up in the WHI, there was no increase in overall mortality, including death rates from cancer, in women taking HRT for up to 5.6 years (estrogen plus progestin) or 7.2 years (estrogen alone). There was a non-significant reduction in mortality among those who started HRT between ages 50 and 59, the group most likely to ...
Source: The Blog That Ate Manhattan - Category: Primary Care Authors: Tags: Hormone Replacement Menopause WHI breast cancer estrogen HRT Prempro Source Type: blogs
Five years of adjuvant therapy with anti-estrogens reduce the incidence of disease progression by about 50% in estrogen receptor-positive breast cancer patients, but late relapse can still occur after anti-estrogens have been discontinued. In these patients, excessive androgen production may account for renewed excessive estrogen formation and increased risks of late relapse. In the 50% of patients who do not benefit with anti-estrogens, the effect of therapy is limited by de novo or acquired resistance to treatment. Androgen receptor and epidermal growth factor receptor overexpression are recognized mechanisms of endocrin...
Source: Endocrine-Related Cancer - Category: Endocrinology Authors: Tags: Commentary Source Type: research
This study investigates whether antral follicle count (AFC) is associated with the presence of menses and time to return of menses, independent of age, in pre-menopausal breast cancer patients after chemotherapy.
Source: Fertility and Sterility - Category: Reproduction Medicine Authors: Tags: Poster session Source Type: research
More News: Breast Cancer | Cancer | Cancer & Oncology | Hormones | Men | Menopause | Ovarian Cancer | Ovaries | Statistics | Study | Women